The Evidence
The NIH maintains a database called LiverTox that rates how often each compound shows up in cases of liver injury. Semaglutide is rated Likelihood Score D, and the database is direct on the verdict: liver injury from semaglutide may occur but is very rare.
Significant weight loss tends to *improve* fatty liver disease, not worsen it.
The Pattern
When people report pain in the area of the liver while on these peptides, the underlying issue is usually the gallbladder, not the liver itself. Right-upper-quadrant pain during rapid weight loss is much more often biliary (the bile duct and gallbladder) than hepatic (the liver itself).
What this means
References1 sources
How to read these sources
This article uses primary sources and reviews to separate mechanism, human evidence, and context.
- Public Update
LiverTox
National Institutes of Health / NIDDKLiverTox: Semaglutide Read source
Used Here ForGrounding the liver-damage question in the NIH's clinical drug-injury database entry for semaglutide.
Good ForAn authoritative, regularly updated summary of a drug's documented liver-injury likelihood.
Not ForA peer-reviewed causal study or personal liver-health assessment.
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, NCBI Bookshelf, updated June 20, 2025